Lab Manager | Run Your Lab Like a Business
Newly developed inhibitor (green) prevents METTL16 (purple) from interaction with target RNA (turquois) and thus inhibits the transfer of the methyl group (Me).
MPI of Molecular Physiology

A Promising Target for New RNA Therapeutics Now Accessible

First inhibitors of the cancer-related RNA-modifier METTL16 identified, opening up potential for new therapeutic options

Max Planck Institute of Molecular Physiology

Every day the trillions of cells in our bodies ensure that we are able to see, think, speak and move. How does each cell ‘know’ what to do? How can...

ViewFull Profile.
Learn about ourEditorial Policies.
Register for free to listen to this article
Listen with Speechify

Chemists in Dortmund have identified the first inhibitors of the cancer-related RNA modifier METTL16 and have thus taken a first step toward new therapeutic options.

RNA has long been considered only as a passive messenger in the cell, produced by DNA transcription to transfer genetic information to the protein factories, the ribosomes. However, it has turned out that RNA does much more than that. In addition to the coding DNA just described, there is also non-coding DNA controlling many cellular processes by regulating the activity of genes at many levels. No less than a dozen RNA classes have been identified nowadays. RNAi, for example, is used by the cell to degrade particular RNA targets to silence genes when it comes to fighting foreign viral DNA.

Get training in Lab Crisis Preparation and earn CEUs.One of over 25 IACET-accredited courses in the Academy.
Lab Crisis Preparation Course

Readers, writers, and erasers

RNA interacts with a plethora of biomolecules, not only other RNAs or DNA but also proteins and metabolites. The resulting regulatory complexes control diverse vital cellular processes, and errors can cause diseases. RNA’s fate is determined by chemical modifications that affect its stability, structure, and interactions and thereby its fate. More than 170 distinct RNA modifications have been described so far. The most abundant is the methylation on the N6-position of the RNA-nucleotide adenosine (m6A). It allows the cell to quickly respond to environmental changes by initiating appropriate cellular responses, such as division, differentiation, or migration. This is why RNA-methylation needs to be tightly controlled, taken care of by a set of proteins: “writers” deposit, “readers” recognize, and “erasers” remove the methyl group.

New substance prevents writing to RNA

Aberrant RNA methylation has been associated with cancers and other human diseases, making “writers” an attractive therapeutic target. Only a handful of RNA m6A writers have been identified so far. And only for one of them, METTL3, potent inhibitors have been reported. These molecules prevent the writer from absorbing the ink, the biomolecule S-adenosyl methionine (SAM). The group of Peng Wu has now identified the first inhibitor of the writer METTL16. However, in contrast to the before-mentioned inhibitors, it showed a different mode of action: it prevents the interaction of METTL16 with RNA. The scientists were able to identify this new type of inhibitor by developing an assay evaluating the disruption between METTL16 and a fluorophore-labeled mRNA substrate.

“Certain cancer cells have elevated writer levels and are also more vulnerable to reduction of SAM levels, which makes them promising anticancer targets. However, the exact biological consequences of METTL16’s binding to RNA substrates are not yet clearly determined. With our work, we lay the foundation for a better investigation of the role of METTL16 in disease and health, but also for the development of novel RNA-targeting therapeutics”, says Peng Wu.

- This press release was originally published on the Max Planck Institute of Molecular Physiology website and has been edited for style and clarity